KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 141 filers reported holding KARYOPHARM THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,399,591 | +85.1% | 1,044,471 | +147.3% | 0.00% | – |
| Q2 2023 | $755,945 | -73.3% | 422,316 | -41.9% | 0.00% | – |
| Q1 2023 | $2,826,823 | -35.5% | 726,690 | -43.6% | 0.00% | – |
| Q4 2022 | $4,384,085 | -25.6% | 1,289,437 | +19.4% | 0.00% | -100.0% |
| Q3 2022 | $5,896,000 | -45.2% | 1,079,881 | -54.8% | 0.00% | 0.0% |
| Q2 2022 | $10,763,000 | -48.1% | 2,386,698 | -15.1% | 0.00% | -66.7% |
| Q1 2022 | $20,728,000 | +202.4% | 2,812,563 | +163.9% | 0.00% | +200.0% |
| Q4 2021 | $6,854,000 | -37.8% | 1,065,619 | -43.7% | 0.00% | 0.0% |
| Q3 2021 | $11,017,000 | -35.0% | 1,892,933 | +15.2% | 0.00% | -50.0% |
| Q2 2021 | $16,952,000 | -5.1% | 1,642,681 | -3.3% | 0.00% | -33.3% |
| Q1 2021 | $17,868,000 | +55.4% | 1,698,473 | +128.6% | 0.00% | +50.0% |
| Q4 2020 | $11,501,000 | +80.9% | 742,913 | +70.6% | 0.00% | +100.0% |
| Q3 2020 | $6,359,000 | +87.1% | 435,578 | +142.8% | 0.00% | 0.0% |
| Q2 2020 | $3,398,000 | +196.8% | 179,418 | +201.1% | 0.00% | – |
| Q1 2020 | $1,145,000 | -47.2% | 59,585 | -47.3% | 0.00% | -100.0% |
| Q4 2019 | $2,168,000 | +36.9% | 113,068 | -31.3% | 0.00% | – |
| Q3 2019 | $1,584,000 | +129.6% | 164,636 | +42.9% | 0.00% | – |
| Q2 2019 | $690,000 | -28.1% | 115,174 | -29.9% | 0.00% | – |
| Q1 2019 | $960,000 | +19.4% | 164,317 | +91.4% | 0.00% | – |
| Q4 2018 | $804,000 | -52.4% | 85,853 | -13.5% | 0.00% | – |
| Q3 2018 | $1,689,000 | -8.2% | 99,198 | -8.4% | 0.00% | – |
| Q2 2018 | $1,839,000 | -7.2% | 108,271 | -26.7% | 0.00% | -100.0% |
| Q1 2018 | $1,981,000 | +195.2% | 147,612 | +111.1% | 0.00% | – |
| Q4 2017 | $671,000 | -0.6% | 69,928 | +13.6% | 0.00% | – |
| Q3 2017 | $675,000 | +140.2% | 61,541 | +98.3% | 0.00% | – |
| Q2 2017 | $281,000 | -80.4% | 31,036 | -72.3% | 0.00% | – |
| Q1 2017 | $1,436,000 | -25.5% | 111,876 | -45.5% | 0.00% | – |
| Q4 2016 | $1,928,000 | +1001.7% | 205,112 | +1047.4% | 0.00% | – |
| Q3 2016 | $175,000 | +400.0% | 17,877 | +246.1% | 0.00% | – |
| Q2 2016 | $35,000 | -81.8% | 5,166 | -76.0% | 0.00% | – |
| Q1 2016 | $192,000 | -25.3% | 21,494 | +10.9% | 0.00% | – |
| Q4 2015 | $257,000 | -81.7% | 19,376 | -85.5% | 0.00% | -100.0% |
| Q3 2015 | $1,405,000 | +67.9% | 133,433 | +333.9% | 0.00% | – |
| Q2 2015 | $837,000 | -52.7% | 30,750 | -46.7% | 0.00% | -100.0% |
| Q1 2015 | $1,768,000 | -1.2% | 57,740 | +20.8% | 0.00% | 0.0% |
| Q4 2014 | $1,789,000 | +5.5% | 47,811 | -1.5% | 0.00% | 0.0% |
| Q3 2014 | $1,696,000 | -19.5% | 48,537 | +7.3% | 0.00% | 0.0% |
| Q2 2014 | $2,106,000 | +349.0% | 45,231 | +198.0% | 0.00% | – |
| Q1 2014 | $469,000 | -82.9% | 15,180 | -87.3% | 0.00% | -100.0% |
| Q4 2013 | $2,739,000 | – | 119,481 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $35,031,000 | 23.03% |
| Palo Alto Investors LP | 5,267,652 | $81,543,000 | 4.28% |
| Fairmount Funds Management LLC | 702,351 | $10,872,000 | 3.89% |
| Birchview Capital, LP | 188,000 | $2,910,000 | 1.68% |
| Mesirow Financial Investment Management, Inc. | 22,303 | $345,250,000 | 1.09% |
| EMERALD ADVISERS, LLC | 1,822,781 | $28,217,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,661,236 | $25,716,000 | 0.90% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,552,504 | $24,033,000 | 0.85% |
| Altium Capital Management LP | 133,951 | $2,074,000 | 0.77% |
| Hood River Capital Management LLC | 931,754 | $14,424,000 | 0.48% |